Yantai, July 25, 2024 – Boan Biotech today announced that its investigational drug candidate, a novel CD228-directed antibody drug conjugate (ADC) for injection codenamed BA1302, has been approv...
Boan Biotech announced today that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has accepted the Biologics License Application (BLA) for the com...
Boan Biotech announced today that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has accepted the Biologics License Application (BLA) for its Dul...
Boan Biotech today announced that Boluojia®, a denosumab injection (120mg) developed by the company, has been approved for marketing by China’s National Medical Products Administration (NMPA) fo...